The use of triptans is contraindicated in patients with migraine and a history of ischemic stroke or coronary artery disease, although there’s no substantial evidence that they directly increase the risk for vascular events.
Presenting at AHS 2022, researchers assessed the efficacy of a 1-year treatment period with ubrogepant 50 or 100 mg in patients with migraine attacks with mild and moderate or severe pain.
Presenting at AHS 2022, researchers evaluated the real-world effectiveness of ubrogepant in combination with onabotulinumtoxinA to treat breakthrough migraine.
The NDA submission includes data from 2 pivotal studies that evaluated zavegepant in adults with at least a 1-year history of migraine and migraine attacks.
Researchers sought to assess the short-term benefit and risk of ticagrelor with aspirin in patients with acute mild-moderate ischemic stroke or high-risk transient ischemic attack.
